Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

ASCO: Trial Creates Six Percent Weight Loss After Breast Cancer Treatment

By Drug Discovery Trends Editor | May 28, 2015

Dr. Tim Byers and colleagues report clinical trial results of intervention creating 6 percent weight loss after breast cancer treatment. Credit: University of Colorado Cancer CenterCarrying extra body fat increases the risk for diabetes, heart disease and stroke, and also increases risk of cancer recurrence after a breast cancer diagnosis. A multi-institutional study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 shows that female breast cancer survivors are able to lose weight through modest lifestyle changes.
 
“This is a significant finding because it shows that women are able to lose weight after breast cancer treatment and this may lead to reduced risk of recurrence,” says Tim Byers, MD, MPH, associate director for cancer prevention and control at the University of Colorado Cancer Center, and one of the study’s authors.
 
“I think these findings show that we should now move forward with a larger study,” says Byers. “If we can prove that intentional weight loss reduces breast cancer recurrence I believe weight control will become a routine part of oncology care.”
 
The study, which lasted two years, followed 700 women at four sites around the United States (Denver, San Diego, Saint Louis, and Birmingham).
 
“The study was a randomized control trial in which half of the participants took part in lifestyle interventions. The goal was to lose seven percent of their body weight and maintain it for two years,” says Rebecca Sedjo, PhD, assistant researcher professor at CU Cancer Center, and collaborator in the trial. In the first 12 months the average weight loss for the intervention group was six percent of their body weight.
 
In order to make lifestyle changes the women in the intervention group attended motivational meetings that focused on increasing physical activity and decreasing caloric intake. The meetings tapered off from once a week to once a month in the first year. In the second year, newsletters were sent to participants to encourage continued weight control.
 
“We don’t need to focus on getting to the ‘ideal’ body type, whatever that may be,” says Byers. “If we can prove that modest weight loss improves the chance of better outcomes after breast cancer we need to encourage and support that.”
 
Source: University of Colorado Denver

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50